Could BIONIK LABORATORIES CORP (OTCMKTS:BNKL) See a Reversal After Less Sellers Came In?

April 19, 2018 - By Marie Mckinney

Bionik Laboratories Corp. (OTCMKTS:BNKL) Logo

The stock of BIONIK LABORATORIES CORP (OTCMKTS:BNKL) registered a decrease of 75% in short interest. BNKL’s total short interest was 100 shares in April as published by FINRA. Its down 75% from 400 shares, reported previously.

It closed at $0.0649 lastly. It is down 0.00% since April 19, 2017 and is . It has underperformed by 11.55% the S&P500.

Bionik Laboratories Corp., a robotics company, focuses on providing rehabilitation and mobility solutions to individuals with neurological and mobility challenges from hospital to home. The company has market cap of $16.31 million. The firm specializes in designing, developing, and commercializing physical rehabilitation technologies, prosthetics, and assisted robotic products. It currently has negative earnings. It offers InMotion Systems, which include the InMotion ARM that allows clinicians to deliver sensor motor therapy to the shoulder and elbow to develop new neural pathways; InMotion ARM/HAND, an add-on module to be used with the InMotion ARM; and InMotion WRIST, a medical device that enables clinicians to deliver optimum intensive sensor motor wrist and forearm therapy to patients with neurological conditions.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.